Ask AI
See Activity Collection
ProCE Banner Activity

mTNBC Practice Readiness: Applying Current Standards and Interpreting Emerging First-line TROP2 ADC Evidence for Immunotherapy-Ineligible Patients

Slideset

Explore current and emerging phase III evidence for TROP2 ADCs in patients with metastatic triple-negative breast cancer who are ineligible for immunotherapy, including implications for patients and healthcare teams when selecting first-line and later-line treatments. Examine how patient characteristics, prior treatment exposure, comorbidities, and distinct adverse event profiles inform individualized care, along with multidisciplinary strategies for toxicity prevention, monitoring, supportive care, and dose modification.

Released: September 08, 2026

Begin Activity

Share

Faculty

Thomas Bachelot

Thomas Bachelot, MD, PhD

Chair, Unicancer National Breast Cancer Group – UCBG
Department of Medical Oncology
Léon Bérard Center
Lyon, France
Rupert Bartsch

Rupert Bartsch, MD

Director, Breast Cancer Programme
Division of Oncology
Department of Medicine I
Medical University of Vienna
Vienna, Austria
Giuseppe Curigliano

Giuseppe Curigliano, MD, PhD

Director of the Early Drug Development Division
European Institute of Oncology
Full Professor of Medical Oncology at University of Milano
Milan, Italy 

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity is intended for oncologists and the multidisciplinary team caring for patients with metastatic triple-negative breast cancer, including advanced practice providers, nurses and nurse navigators, patient navigators, pharmacists, and eye care specialists (ophthalmologists and optometrists).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Interpret current and emerging clinical evidence for TROP2 ADC–based strategies in immunotherapy-ineligible mTNBC, including implications for first-line and later-line treatment planning

  • Individualize treatment selection and sequencing for patients with mTNBC who are not candidates for immunotherapy, integrating prior therapy exposure, disease burden, comorbidities, toxicity risk, and patient preferences

  • Implement multidisciplinary monitoring, toxicity-prevention, and AE-management pathways for patients receiving TROP2-directed therapy, including timely triage and oncology–eye care coordination when clinically indicated